U.S. stock night market volatility: KRAS vaccine phase II failure causes stock price to plummet 73%, further decline of 14% in night trading

U.S. Stock Night Market Movements

Elicio Therapeutics fell 14.23% in the night market. Based on recent key news:

1. On June 15, Elicio Therapeutics' ELI-002 7P vaccine failed to prevent disease recurrence in a mid-stage study involving pancreatic cancer patients, leading to a significant drop in stock price by 50%. The company plans to conduct follow-up research in R0 resected patients.

2. On June 16, the company announced it would focus on a Phase 3 development strategy for R0 resected patients, planning to use disease-free survival as the primary endpoint, which continued to pressure the stock price.

3. On June 17, Elicio Therapeutics planned to conduct a Phase 1 trial of ELI-002 7P in combination with chemotherapy and anti-PD-1 drugs. Despite previous data showing immunotherapy potential, market reaction was negative, leading to a decline in stock price. The biotechnology industry has been highly volatile recently, and investment should be approached with caution.

Stocks with High Trading Volume in the Industry

Moderna rose 0.68% in the night market. Based on recent key news:

1. On June 16, FDA documents indicated a positive stance on Moderna's flu vaccine, driving the stock price up by 2.5%. The FDA's documents noted that Moderna's flu vaccine showed a strong immune response in adults aged 65 and older, boosting investor confidence and leading to a stock price increase.

2. On June 17, Moderna announced plans to invest in production facilities in Germany, with the stock price rising about 12%. According to German media reports, Moderna intends to invest in a factory that BioNTech plans to close, making it the largest gainer in the S&P 500 index.

3. On June 17, Moderna's stock price rose 1.19% in pre-market trading, reaching $56.06. According to data from Benzinga Pro, this increase reflects market optimism regarding the potential approval of its flu vaccine. The vaccine industry is closely monitoring the progress of flu vaccines, with significant market volatility.

Recursion rose 1.93% in the night market. Recursion Pharmaceuticals had no significant news recently; trading was active with clear capital flows. Considering sector and industry trends, the stock showed notable volatility, and specific reasons need further observation. no_news

Sarepta Medical fell 0.83% in the night market, with a trading volume of $11,800, and had no significant news recently. Trading was active with clear capital flows. Considering sector and industry trends, the stock showed notable volatility, and specific reasons need further observation